small nuclear ribonucleoprotein polypeptide G pseudogene 11Genealiases: []
Q-omics provides the consensus-scored SNRPGP11 profile across patient tissues and cancer cell-line models. SNRPGP11 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SNRPGP11 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, SNRPGP11 RNA expression shows 5,304 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, HNSC, and STAD as cancer lineages where SNRPGP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPGP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPGP11 survival associations across molecular data types. SNRPGP11 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPGP11 RNA expression–survival associations across cancer types. High SNRPGP11 expression shows unfavorable associations in BLCA, LUSC, ACC, SARC and LAML, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SNRPGP11 RNA expression.
This table summarizes SNRPGP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPGP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPGP11 shows higher tumor expression in HNSC. The HNSC box plot shows higher SNRPGP11 RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p = .033).
This table shows molecular features associated with SNRPGP11 in patient tissues and cancer cell lines. In patient samples, SNRPGP11 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
